Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$3.01M$3.01Mderived+31.2% vs Q4 2022 Net Income-$1.31M-$1.31MderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$464,000+383.3% Operating Incomederived-$1,150,000N/M Operating Cash Flowderived-$2,441,000N/M Free Cash Flowderived-$2,631,000N/M Margins · derivedGross margin15.4%+11.2 pt vs Q4 2022
Operating margin-38.2%+95.0 pt vs Q4 2022
Net margin-43.4%+84.7 pt vs Q4 2022
ended Mar 31, 2023 · filed Jun 21, 2023 · 82 d after period end